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Abstract  
Stroke is the second largest cause of disability-adjusted life-years worldwide. The prevalence 
of stroke in women is predicted to rise rapidly, owing to the present increase in the global 
elderly [aging rather than elderly?] female population. Vascular risk factors differ between 
women and men in terms of prevalence, but evidence also increasingly supports the clinical 
importance of sex differences in stroke. The influence of some risk factors for stroke — 
including diabetes mellitus and atrial fibrillation — are stronger in women, and hypertensive 
disorders of pregnancy also affect the risk of stroke decades after pregnancy. However, in an 
era of evidence-based medicine, women are notably underrepresented in clinical trials — 
despite governmental actions highlighting the need to include both men and women in 
clinical trials — resulting in reduced generalizability of study results to women. The aim of 
this Review is to highlight new insights into specificities of stroke in women, to plan future 
research priorities and to influence public health policies to decrease the worldwide burden of 
stroke in women. 
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Key points 
 Hypertension and atrial fibrillation are more frequent in women than in men. 
 The effect of some risk factors — including diabetes mellitus and atrial fibrillation — 
are stronger in women than in men 
 Hypertensive disorders of pregnancy are important causes of stroke in pregnancy, 
with intracerebral haemorrhage being the leading cause of maternal death. 
 Women are underrepresented in clinical trials despite governmental actions 
highlighting the need for inclusive and nondiscriminatory trials that include both men 
and women  
 Women are more difficult to include in stroke trials than men, because they tend to be 
older at stroke onset have more comorbidities, and tend to live alone.  
 Women living in societies with low access to education and hence to adequate 
healthcare have especially little awareness of stroke 
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Box 1 | Areas for development: 
1. Data regarding stroke in women should be collected in all countries in order to develop 
specific actions tailored to each society structure and healthcare system. 
2. Major sex differences in presentation and the effect of risk factors suggest a possible 
benefit from personalized medicine —including investigation and treatment — for women 
with stroke. 
3. Early detection and treatment of hypertensive disorders of pregnancy (HDP) should be 
promoted. A clear understanding of the aetiology of HDP could lead to the development of 
preventative strategies. 
4. Future studies assessing hormone replacement therapy early after menopause should 
focus on robust clinical endpoints to personalize stroke treatment based on women’s 
individual risk of stroke. 
5. More evidence is urgently required regarding the effects of treatment interventions in 
elderly women with stroke, particularly in stroke related to atrial fibrillation, and how these 
interventions influence cardiovascular outcomes in women.  
6. Data are needed on the incidence of inherited thrombophilia and prevention of cerebral 
venous thrombosis in individuals at a high risk of these conditions. Randomized controlled 
trials or high quality registry data are needed to better assess therapeutic interventions.  
7. Large-scale cohort studies into the risk factors for intracerebral haemorrhage in women 
are required to confirm whether women have worse outcome following intracerebral 
haemorrhage than do men, independent of age and premorbid functional status, and whether 
this association is related to a difference in care. 
8. Educational campaigns for stroke awareness in women should include stroke symptoms 
and time-dependent therapeutic options, and should be tailored to different societal models 
worldwide.  
9. Enrolment age limits for randomized controlled trials should be avoided, and enrolment 
should instead mirror the sex distribution of the disease being investigated. 
10. Barriers to access to care and rehabilitation in women should be identified and 
addressed to provide equal access to both sexes. 
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In 2015, stroke became the second largest cause of disability-adjusted life-years   worldwide, 
behind ischaemic heart disease1. With an anticipated increase in the average age of the 
female population worldwide , the prevalence of stroke in women is projected to rapidly 
increase, particularly among elderly women, leading to challenges for healthcare systems2. 
Stroke is not only a leading cause of disability, but is also a leading cause of death worldwide 
— particularly in women, in whom mortality due to stroke consistently exceeds that in men. 
The WHO reported an excess of total stroke-related deaths among women compared with 
men, of which 60% occurred in those aged over 75 years3. 
 
Women differ from men in a multitude of ways, including anatomy, vascular biology, 
immunity, neuroprotective factors, hormonal profiles, vascular risk factors, and lifestyle 
factors and societal roles. All of these factors might influence the risk of stroke and affect 
prognosis4. The aim of this Review is to highlight new insights into specificities of stroke in 
women, to plan future research priorities and to influence public health policies to decrease 
the burden of stroke on women worldwide. 
 
[H1] Epidemiology 
In 2009, a review of 56 population-based studies from high-income countries revealed a 42% 
decrease in worldwide stroke incidence rates from 163 per 100,000 person–years in 1970–
1979 to 94 per 100,000 person–years in 2000–2008. A faster decline in incidence was 
observed in men than in women5. Data from the Framingham Heart Study also suggested 
that one in five women and one in six men who reach the age of 55 years free from stroke 
will develop a stroke event during their remaining lifetime6.  
A meta-analysis of individual participant data from high-quality stroke incidence studies  
confirmed that women consistently have greater long-term mortality than do men after stroke, 
regardless of study location and time period. In women, advanced age, more-severe strokes, 
worse prestroke function, and the presence of atrial fibrillation contributed to a greater 
mortality after stroke compared with men 7.  
The quality and the availability of data regarding stroke in women is highly heterogeneous 
between countries. Rigorous evaluation of the epidemiology of stroke among women is 
difficult in some regions of the world8. The data on case fatality of stroke provide evidence for 
considerable variation among countries, even when studies with strict criteria for inclusion 
are focussed on9. Ethnicity could contribute to this variation, but little data exist on this topic, 
especially regarding the potential for sex differences to be influenced by ethnicity. Women 
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from some countries might be excluded from epidemiological data because they are not 
admitted to hospital, or because ascertainment and diagnosis patterns might be different in 
men compared with women2. Moreover, data from the GBD 2013 study highlighted that 
women are unequal to men when suffering from stroke throughout the world: in some regions 
of the world mortality due to stroke is higher in women than in men  . This inequity is strongly 
associated with socioeconomic status: the majority of the countries where women had higher 
stroke mortality rates than men were developing countries and/or underwent negative 
historical events, such as natural disaster or war, within the past few years 2. Consequently, 
data on incidence and case fatality of stroke in women should be collected in all countries to 
develop specific actions to address this issue that are tailored to each society structure and 
healthcare system.  
 
[H1] Specific risk factors of ischemic stroke  
Evidence increasingly shows that risk factors for stroke differ between men and women: 
frequencies of vascular disease vary between the sexes and some risk factors are specific to 
women. Stroke onset is later in women than in men, and rates of hypertension (60% versus 
56%) and atrial fibrillation (24% versus 22%) are higher in women than in men. Conversely, 
rates of diabetes mellitus (16% versus 20%) and smoking (15% versus 16%) are higher in 
men than in women10. Differences in smoking rates are decreasing between sexes, but 
smoking still has a male preponderance11.  
Some female-specific characteristics increase the risk of stroke, including gestational 
hypertension (relative risk (RR) 1.51; 95% CI 1.27–1.80), oophorectomy (RR 1.42; 95% CI 
1.34–1.50), preterm delivery (RR 1.62; 95% CI 1.46–1.79), and still birth (RR 1.86; 95% CI 
1.15–3.03), whereas hysterectomy is possibly protective against stroke (RR 0.88; 95% CI 
0.85–0.90)12. Furthermore, the effect of some individual risk factors seems to be stronger in 
women than in men. Atrial fibrillation is associated with double the risk of stroke in women 
compared with the risk in men (RR 1.99; 95% CI 1.46–2.71) 13. In a study based on 12,701 
patients with cardio-embolic strokes, women with atrial fibrillation underwent more-severe 
strokes than men (median NIH Stroke Scale 14 versus 8)14. The excess risk of stroke from 
diabetes mellitus is higher in women than in men: RR 2.28 (95% CI 1.93–2.69) versus 1.83 
(95% CI 1.60–2.08)15. This result is in line with findings in metabolic syndrome in which 
women in a large scale meta-analysis had a larger risk of stroke (with an RR of 1.83; 95%CI: 
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1.31–2.56) than men (RR 1.47; 95%CI 1.22–1.78)16. Data on abdominal obesity also suggest 
a stronger effect on stroke risk among women than men17. 
Other risk factors have the same effect in men and women. A systematic review and meta-
analysis based on 1.2 million individuals concluded that the effect of systolic hypertension 18 
or increased total cholesterol19 was equal in men and women. Evidence is inconclusive with 
regard to why certain risk factors have a stronger effect on women than men. Suggested 
explanations include the under-treatment of women, and physiological differences between 
the sexes13, 20. The different burden of risk factors in both sexes needs to be thoroughly 
explored to personalize prevention and treatment. In this regard, screening programs or 
interventions for type 2 diabetes mellitus or atrial fibrillation in women could carry 
considerably more benefit compared with those in men.  
[H1] Three periods of stroke risk in women  
Risk of stroke differs throughout the lifecourse. Here we will examine the factors associated 
with increased stroke risk in women at three stages of life: women of child-bearing age, 
postmenopause women and women over 80 years of age.  
[H2] Child-bearing age 
[H3] Oral contraceptives. Hormonal contraception is common and its use is increasing: four 
of five sexually active women have taken the oral contraceptive pill in the USA21. Worldwide 
use of the oral contraceptive pill varies considerably between regions, from less than 10% of 
total anticonception use in developing countries to more than 25% in Europe 22. A 2015 
meta-analysis showed that combined hormonal contraception increased the risk of stroke 
2.47-fold (95% CI 2.04–2.99). Low dose estrogen was associated with a reduced stroke risk, 
whereas the type of progesterone was not associated with stroke risk. No excess risk was 
observed in gestagen-only formulations23. A 1.7-fold (95% CI 1.5–1.9) increase in risk of 
stroke resulting from combined oral contraceptives was found in a systematic review24. 
Despite the fact that crude incidence of stroke in relation to hormonal contraceptives is very 
low (the crude incidence rate of ischaemic stroke was 21.4 per 100,000 person–years)25, the 
observed increase in risk remains important as other modifiable risk factors might exist in 
healthy women. However, study findings underline that hormonal contraception is a very rare 
cause of ischaemic stroke and should be considered as such in clinical care. 
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[H3] Pregnancy. The increased risk of stroke in pregnancy is well recognized, particularly 
around the time of delivery. Reported rates of stroke incidence vary from 2.5–34 cases per 
100,000 deliveries26. The rate of stroke increases ninefold at the time of delivery and 
threefold in the early postpartum period, with an increase in both ischaemic and 
haemorrhagic stroke.  
Hypertensive disorders of pregnancy (HDP) (FIG. 1), a spectrum that includes gestational 
hypertension (blood pressure>140/90mmHg), pre-eclampsia (hypertension with proteinuria) 
and eclampsia (seizures) are a leading cause of maternal and perinatal morbidity and 
mortality worldwide1. The exact aetiology is unclear. Although only 1% of patients with pre-
eclampsia undergo a stroke, pre-eclampsia is the most common cause of stroke in 
pregnancy27 (FIG. 1). However, the effects of HDP persist beyond pregnancy, resulting in 
increased vascular disease28 and mortality later in life29. Women with HDP are usually 
unaware of the long-term cardiovascular risks of this condition and long-term follow-up 
should be encouraged30.  
Intracranial haemorrhage is the leading cause of maternal death31 and the majority of 
haemorrhages are due to HDP32. Management of pre-eclampsia and intracerebral 
haemorrhage (ICH) in pregnant women should focus on rapid, aggressive, blood pressure 
control in combination with delivery of the baby as soon as possible33. Notably, pregnant 
women with haemorrhagic stroke are younger, have fewer comorbidities and have a better 
outcome than nonpregnant women with haemorrhagic stroke34. Other neurological 
syndromes, such as reversible cerebral vasoconstriction syndrome — an important cause of 
pregnancy-associated stroke36 —and posterior reversible encephalopathy can occur as a 
consequence of HDP35 (FIG. 3).  
Unenhanced CT remains the standard first-line imaging technique for the investigation of 
suspected stroke in pregnancy in many medical centres worldwide, but early use of MRI can 
distinguish between stroke and other neurological conditions37. In the context of HDP and 
neurological symptoms, MRI can help to differentiate permanent lesions (resulting from 
cytotoxic oedema) versus reversible lesions (resulting from vasogenic oedema) . Moreover, 
MRI enables assessment of intracranial vessels to diagnose reversible cerebral 
vasoconstriction syndrome.  
Until the past few years, reports of use of thrombolysis and other reperfusion strategies had 
been limited to small case reviews, with uncertainty surrounding the use of thrombolysis in 
pregnancy. Although alteplase does not cross the placenta,  some concerns surround the 
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use of this drug in pregnancy, particularly regarding the potential for placental haemorrhage. 
In the large US Stroke Registry ‘Get with the Guidelines’, pregnant women with ischaemic 
stroke, were less likely to receive thrombolysis with alteplase (4.4%) than were nonpregnant 
women (7.9%, P = 0.03) despite significantly  greater stroke severity in pregnant women. In 
pregnant or postpartum patients who were treated with alteplase, no increase in systemic 
bleeding was detected, but a nonsignificant increase in the risk of symptomatic ICH was 
found38. Notably, the majority of stroke related to pregnancy occurred during the postpartum 
period39. Use of intra-arterial therapy for ischaemic stroke has been reported in a number of 
case series, and could be preferable to thrombolysis when the risk of maternal haemorrhage 
is high40.  
The presence of a patent foramen ovale in pregnancy is associated with increased risk of 
stroke in individuals with prothrombotic risk factors — including activated protein C 
resistance and reduced blood levels of protein S. However, in contrast to other stroke risk 
factors, risk of stroke owing to a patent foramen ovale peaks during the first and second 
trimesters of pregnancy. Pregnant women with hypercoagulable states should be considered 
for antithrombotic therapy with low-molecular-weight heparin, but patent foramen ovale is not 
a barrier to normal healthy delivery41.  
In conclusion, to promote early detection of HDP, patients should undergo aggressive 
treatment of high blood pressure and management of conventional risk factors before, 
during, and after pregnancy. A clearer understanding of the aetiology of HDP could lead to 
development of preventative strategies for this condition. Prospective registries are 
necessary to evaluate treatment strategies (such as thrombolysis and endovascular 
reperfusion) as randomized controlled trials are probably unfeasible. 
 
[H3] Menopause and hormonal replacement therapy. The burden of risk factors for 
vascular dysfunction increases in woman after the menopause42 — presumably owing to the 
postmenopausal decrease in estrogen, a hormone with vascular-protective properties. This 
assumption is consistent with the finding that early menopause increases the risk of stroke. 
According to a meta-analysis of 310,329 women from 32 observational studies, onset of the 
menopause before the age of 45 years increases the relative risks of overall coronary heart 
disease (RR 1.50; 95% CI: 1.28–1.76), overall stroke (RR 1.11; 95% CI 1.03–1.20), 
cardiovascular mortality (RR 1.19; 95% CI 1.08–1.31), and all-cause mortality (RR 1.12; 95% 
CI 1.03–1.21)43.  
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Hormone replacement therapy (HRT) is thought to be vasoprotective, owing to the protective 
properties of estrogen; however, this hypothesis has not been confirmed . A pooled analysis 
of results from randomized controlled trials (RCTs) of stroke prevention from the past two 
decades has even suggested a 30% increase in the risk of stroke in women who receive 
HRT44, in contrast to the apparent protection of HRT against cardiovascular disease that has 
been found in large observational trials45. A higher risk of stroke is associated with a longer 
duration of continuous use of HRT. After 3 years of HRT use, the risk of stroke increases 
from 6 per 1000 to 12 per 1000 treated women. After 7 years of HRT use, risk of stroke 
increased to 25–40 per 1000 women46.  
Results from observational and interventional studies of HRT differed considerably. In the 
observational studies, HRT was generally initiated in relation to the onset of menopause, 
whereas women in RCTs were often enrolled a decade or later after menopause. This 
discrepancy has led to the formation of the ‘timing hypothesis’, which proposes that HRT has 
differing effects on the cardiovascular system at different ages and stages of cardiovascular 
health. Potential vascular protective effects of estrogen include beneficial effects on the 
vascular endothelium and on cardiovascular disease risk factors47. Estrogen has been 
hypothesized to have a beneficial role in early atherogenesis and an adverse role later in the 
disease course48. This idea has led to studies investigating cardiovascular health in women 
early after menopause, with a focus on atherogenesis as an endpoint. However, a 
substantial effect of HRT on increase in carotid artery intima–media thickness (CIMT) was 
not documented: initiation of HRT 6–36 months after last menses did not affect CIMT 
compared with placebo during a 48-month follow-up49. 
In the ELITE (Vascular Effects of Early versus Late Postmenopausal Treatment with 
Estradiol) trial, HRT initiated within 6 years after menopause yielded a significantly smaller 
increase in CIMT after 5 years follow-up than did initiation of HRT 10 years or later after 
menopause, independent of progesterone treatment50. These data suggest that early 
initiation of HRT could have a lower risk of stroke than later initiation.  
A nested case–control study undertaken in France also examined the risk of transdermal 
HRT in women aged 51–62 years. No association was found between ischaemic stroke and 
use of progesterone (OR 0.78; 95% CI 0.49–1.26), pregnanes (OR 1.00; 95% CI 0.60–1.67), 
or nortestosterones (OR 1.26; 95% CI 0.62–2.58), whereas norpregnanes increased the risk 
of ischaemic stroke (OR 2.25; 95%CI 1.05–4.81)51. These results are consistent with a 
previous case-nested control study that found no increased risk of stroke with transdermal 
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HRT52. Future studies assessing HRT early after menopause should focus on robust clinical 
endpoints to personalize treatment based on individual risk.  
[H3] Women aged over 80 years. Elderly women represent a large proportion of the total 
stroke population and have more-severe strokes53, poorer outcome 54-56, and more-limited 
access to care57 than other demographics. Secondary prevention is far from optimal in this 
high-risk group: elderly women have a decreased likelihood of having adequate blood 
pressure control after stroke58, being treated with antithrombotic drugs, and receiving 
anticoagulation treatment when found to have atrial fibrillation56. Management  of atrial 
fibrillation is crucial if we are to decrease the burden of stroke among elderly women, but 
data on this issue remain insufficient and conflicting59, 60. One study found that women had 
an increased risk of stroke and a reduced quality of life compared with men, despite similar 
anticoagulation use.61. The paucity of data from RCT among elderly women could contribute 
to these findings; consequently, more research into stroke in elderly women is urgently 
required. Future studies should focus on how treatment and interventions affect quality of life 
and cardiovascular outcomes related to atrial fibrillation in women. 
 
[H2] Psychosocial factors and depression 
An increased risk of stroke risk has inconsistently been reported in individuals exposed to 
various psychosocial stressors. Psychosocial factors can include psychological, behavioural, 
vocational, and interpersonal processes that may be associated with social disruption, social 
status and integration. A meta-analysis of 10,130 incidences of stroke found that people with 
perceived psychosocial stress (defined as self-reported sensation of tension, irritability, 
nervousness, anxiety or sleeplessness)] ,  exposure to general or work stress or who 
experienced stressful life events (such as loosing a job) had an increased risk of stroke 
(1.33; 95% CI 1.17–1.50), and this increase in risk was higher in women than in men62. The 
Chicago Health and Aging Project assessed psychosocial distress as a composite measure 
of depressive symptoms, perceived stress, neuroticism, and life dissatisfaction, and reported 
that a high distress score in elderly individuals was associated with an increased risk of 
death resulting from stroke, after adjustment for age, race and sex. In this population, women 
reported higher distress scores than did men63. 
Depression is a documented risk factor for stroke and research has suggested a ‘dose-
dependent’ association between higher stroke risk and higher severity of depression 64. An 
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analysis based on a nationwide  sample from Denmak reported that depression was 
predictive of stroke (OR 1.22, 95% CI 1.08–1.38), and that the effect of depression on stroke 
was higher in men than in women (the difference in OR between men and women was 1.30; 
95% CI 1.01–1.68)65. Depression could be associated with an increased risk of stroke 
through a variety of mechanisms. Depression has known neuroendocrine effects (such as 
dysregulation of the hypothalamic–pituitary–adrenocortical axis and dysfunction of platelet 
aggregation)66, and immunological or inflammatory effects67. Moreover, depression can be 
associated with poor health behaviours that might increase stroke risk: in a cohort of more 
than 80,000 nurses in the USA, women with depression were more likely to be single, had a 
higher body mass index, were more likely to smoke cigarettes, and were less likely to be 
physically active44. Whatever the mechanisms are, the idea that women with depression 
could have an increased risk of stroke deserves more recognition. Further research is 
necessary to determine whether the risk associated with depression can be reduced by 
specific interventions. The role of negative historical events (such as war or tsunami) on the 
risk of stroke and the mechanisms of these effects among women should be further 
documented. 
A meta-analysis of prospective cohort studies showed that women with high strain jobs had 
higher risk of stroke than women with low strain (RR 1.33, 95% CI 1.04–1.69); however, this 
difference was not observed in men68. High psychological demands, low job control, and job 
strain were all associated with an increased risk of stroke among working women69. 
However, the data are scarce and conflicting, and the influence of cultural habits (for 
example on whether there is a share of daily responsablities at home) has not been 
explored70. 
Socioeconomic status has also been associated with stroke risk. In a nation-wide study from 
Denmark, the lowest-income group had double the risk of stroke compared with the highest-
income group71. No sex differences were reported in this study, despite the fact that the 
women more often had low income, only basic education and were older than the men 
studied72. Moreover, low education, consistently low income and consistent financial strain 
predicted increasing carotid intima–media thickness in a cohort of women, even after 
adjustment for standard cardiovascular risk factors73.  
Living alone increases the risk of dying from stroke in men (HR 3.47; 95% CI 2.13–5.65), but 
not in women before the age of 70 years74. Men also seem to be more vulnerable to 
unemployment as a stressor, compared with women75. With regards to ambient stressors, 
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pollution has been reported only to affect the risk of stroke in women, but not in men, and 
has an increased effect on women with obesity76.  
 
[H1] Cerebral venous thrombosis   
Cerebral venous thrombosis (CVT) has a female preponderance of 75%77, with a 68% 
preponderance of female patients reported in isolated cortical vein thrombosis78. The sex 
distribution of CVT has shifted over time towards a larger proportion of affected women79, 
possibly owing to increased use of hormonal contraception by women. The 65% of women 
with stroke who have sex-specific risk factors (such as use of hormonal contraception, 
pregnancy, postpartum risk factors, and use of hormone replacement therapy) have much 
better prognosis after CVT than other women and men 77, although differences in 
recanalization rates have not been observed80. Women more often have headache at the 
onset of CVT, and less often a head or neck infection81. Hormonal contraception remains the 
most frequent single risk factor for CVT, and doubles the risk of any venous 
thromboembolism (that is, CVT, deep vein thrombosis or pulmonary embolism)82. The risk of 
CVT increases in pregnancy, with most cases occurring during the postpartum period, and 
risk factors include caesarean section, dehydration and dural puncture after anaesthesia. 
CVT occurring early in pregnancy is often due to inherited thrombophilias. Treatment with 
low–molecular-weight heparin is recommended as the safest option during pregnancy and 
the puerperium83. In women with previous CVT, the absolute risk of pregnancy-related CVT 
was one of 217 pregnancies together with a risk of noncerebral venous thromboembolism 
(VTE) of one of 37 pregnancies83. The risk of CVT is acceptably low in the case of a 
subsequent pregnancy with access to good care; however, the risk of other VTE is high and 
prophylaxis should be considered. Data are needed on the incidence of inherited 
thrombophilia and prevention of CVT in high-risk patients. RCTs or high-quality registry data 
are needed to better assess interventions. Similarly to many other rare conditions, guidelines 
are key for homogenizing the management of CVT in women worldwide. 
 
[H1] Haemorrhagic strokes  
Data are limited regarding sex differences in spontaneous ICH. Available data are based 
mostly on single centre hospital registries, and differences across the populations — such as 
age, ethnicity and location — might contribute to the inconsistent results that are observed. 
Independent of age and stroke severity, women with ICH are treated less aggressively than 
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men. Do-not-resuscitate orders are more common for women84 and women are less-likely to 
be admitted to intensive care units85.  
Although data are inconsistent, women seem to have a worse prognosis than men overall. 
Studies have found that women have an increased risk of dependency as an end-point86, and 
an increased risk of the combined end-point of death or dependency85. However, a meta-
analysis from 2010 that was based on 4,658 patients with ICH recruited before the year 2000 
found no difference in mortality between men and women 87. Case fatality ranged from 16–
52% in women and 19–48% in men. Similar results have also been seen in subsequent 
studies85. Nevertheless, other studies have reported an overall lower88, 89 or of higher risk of 
death in women than in men90.  
ICH outcome in women versus men is influenced by age91, prestroke functional status and 
stroke severity86. Evidence increasingly suggests that sex-specific effects of genetic 
polymorphisms could play a part in sex differences in both the risk and outcome of ICH92.  
Hematoma location might also differ across sexes. In a prospective hospital registry of 515 
patients with ICH in Spain, lobar hematoma location was more common in women (age-
adjusted OR 1.75, 95% CI 1.18–2.58)85. No sex differences in cerebral amyloid angiopathy or 
hypertension were detected at baseline, suggesting explanations other than aetiology85. 
Despite the association with outcome, no sex differences in haematoma volume or 
expansion have been identified; however, women might have less perihaematomal oedema 
than men have 93.  
No efficient acute treatment currently exists for ICH94. Trials have been neutral, male-
dominated and most have not reported subgroup analysis according to sex. The most 
promising treatment has been acute and intensive lowering of blood pressure 95. A small trial 
suggested an association between a faster rate of blood pressure decline and mortality in 
men, but not in women96; however, large-scale clinical trials have not shown differential 
effects of blood-pressure-lowering treatment in subgroups according to sex95, 97. Large-scale 
cohort studies are required to identify specific risk factors for ICH in women. Data are also 
needed to confirm whether women have a worse outcome following ICH than men — 
independent of age and premorbid functional status — and whether this difference is related 
to difference in care. 
 
[H1] Long-term consequences  
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Research has indicated that intravenous thrombolysis is less-effective on functional outcome 
after stroke in women than in men, even after adjustment for age98. Consequently, women 
are more likely to be discharged with more severe neurological deficits than men. In a Dutch 
study of young patients with ischaemic stroke (aged 18–50 years), women had a twofold to 
threefold higher risk of a poor functional outcome than men during 13 years of follow up99. 
Other studies have shown no such difference100, and extrapolation of results is difficult as 
confounding factors such as access to acute care or rehabilitation should also be taken into 
account. 
Return to work after stroke is an important factor for overall life satisfaction in younger men 
and women 101. Nevertheless, in Sweden, men are more likely to be unhappy than women if 
they cannot return to work102, and data from Australia103 and Denmark104, suggest that 
women are less likely to return to work than men. Stroke severity is not the only factor that 
predicts the return to work after stroke: work characteristics (such as manual work, demands 
of flexibility at work) and national healthcare policies, which differ drastically across countries, 
are also important. The duration of official sick-leave is one example.  
Suicide after stroke might reflect the effect of the stroke on the life situation of the individual. 
A study from Sweden indicated that young men were more likely to attempt suicide than 
were women105,  in contrast to an earlier Danish study in which women had a higher risk of 
suicide106. However, in both these studies, people aged below 50 were more at risk than 
older individuals.  
Although no evidence currently supports sex disparities in cognition after stroke (ref), women 
are at an increased risk of neurodegenerative dementia107 because stroke onset occurs at an 
older age in women than in men. The occurrence of stroke has a substantial effect on the 
absolute risk of dementia in the general population; therefore, the prevention of stroke could 
reduce the rate of dementia108. However, the older age at stroke and higher prevalence of 
mood symptoms after stroke in women could affect cognitive performances directly109. 
Studies have reported a lower quality of life in women after stroke, but despite the fact that 
rates of fatigue after stroke seem higher in women than in men, this trend disappears when 
age is adjusted for in a population-based setting110-112. More knowledge of the so-called 
invisible handicaps (cognitive impairment, lack of initiative, extreme fatigue) after stroke is 
needed, particularly regarding the possible sex disparities that are not explained by age  . 
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[H1] Stroke symptoms and risks  
Prompt recognition of stroke symptoms is crucial for timely treatment. Women have a longer 
delay to treatment113, arrive later to hospitals, and receive less frequently acute stroke 
treatment and diagnostic investigation than men114, 115. Reasons for these delays are unclear, 
although they might be due in part to sex-related differences in clinical presentation and 
differences in patients’ knowledge of stroke and response to symptoms55. 
Several studies have sought to evaluate knowledge of stroke symptoms and risk factors by 
the general population, but few have focused on sex differences. Women have been 
reported to possess a better knowledge of major stroke symptoms and stroke risk factors 
than men116. Moreover, women tend to learn from health behaviour and stroke campaigns 
independently of their educational background. One hypothesis may be that women have 
greater interests in health topics than men. 
Despite a better awareness of stroke, women are less likely to call an ambulance for 
themselves and are more likely to have an unknown time of stroke onset than are men117. 
These differences remain after adjustment for age, residence or socioeconomic level — 
factors known to be associated with a more appropriate response to stroke118. This gap 
between knowledge and health behaviour is possibly due to societal factors. Specifically, 
women with stroke in low-income countries tend not to be admitted to hospitals8. Absence of 
universal health-care systems — as well as a lack of stroke units, stroke care pathways and 
stroke guidelines — makes treatment more difficult to deliver in women  . Moreover,  
obstacles to access of education and therein to adequate healthcare created by some 
societies lead to inequities of care independently from the knowledge of stroke symptoms. 8. 
Improved control of risk factors for stroke, better treatment, and implementation of specific 
stroke guidelines for women are needed to reduce stroke incidence in women; these 
initiatives will be complimented by stroke awareness programs, such as the “I am woman” 
campaign by the World Stroke Organisation. This campaign focussed on the burden of 
stroke among women and the responsibility of being the primary caregiver for a family 
member recovering from a stroke. 44, 119. Specific campaigns regarding stroke in women are 
needed that include instructions on stroke symptoms and information on time-dependent 
therapeutic options. These campaigns need to be tailored to different societal models 
worldwide.  
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[H1] Inclusion in clinical trials 
To date, most RCTs and meta-analyses on the use of antithrombotic agents in 
cerebrovascular disease have neither performed subanalyses on sex-related differences nor 
adequately represented women in their samples. One exception was the Women’s Health 
Study, which showed that aspirin was effective in the primary prevention of ischaemic stroke 
among women, without a substantial increase in ICH120. On the other hand, the Men’s Health 
Study reported that aspirin was effective among men in the primary prevention of myocardial 
infarct, but with a slight increase in the risk of ICH121.  
Healthcare authorities sought to rectify the low representation of women in clinical trials with 
the introduction of the NIH Revitalization Act in 1993, which urged for the inclusion of women 
in RCTs122. In 2005, the European Society of Cardiology and the European Medicines 
Agency recommended that there should be a meaningful representation of women in clinical 
trials123. In 2016, the Motion for a European Parliament Resolution on promoting sex equality 
in mental health and clinical research (2016/2096 (INI)) underlined the fact that clinical trials 
of pharmaceutical products on both men and women are necessary, and that these should 
be inclusive, nondiscriminatory and performed under conditions of equality and inclusion124. 
Unfortunately, the male:female ratio in stroke trials still does not reflect the real world 
demographics of stroke. 
Trials from the past few years that focussed on non-vitamin K oral anticoagulants (NOACs) 
illustrate the current situation. NOACs were evaluated in seven RCTs, in which less than 
40% of the people enrolled were women125. To  correspond with epidemiological data, more 
than 50% of the patients in these RCTs should have been women: firstly, because female 
sex is recognized as a risk factor in the CHA2DS2-VASc-score for systemic embolism126, and 
secondly because cardioembolic strokes have a higher fatality rate at 1 month poststroke in 
women than in men127. These seven RCTs did not report any sex differences concerning the 
safety and efficacy of the NOACs. However, the overall mean age of the included patients 
was 71.5 years, almost 4 years lower than the average age of women admitted for 
cardioembolic strokes128.  
Women might be more difficult to include in RCTs than men because they tend to be older at 
stroke onset, have more comorbidities, and are more likely to have pre-existing functional 
impairment. Moreover, they are more likely to live alone than are men. These factors might 
affect the availability of a representative who can give consent for treatment if they lack the 
capacity to give consent themselves. Social aspects also need to be considered: women 
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tend to be the caregivers in families, and in many societies decisions regarding women’s 
health still depend on men. To foster the inclusion of women in clinical trials, age exclusions 
should be considered only in light of safety considerations and not as an arbitrary age cut-off. 
Indeed, trials often do not need to have an age restriction: instead, designs should include 
comorbidities or other health conditions to mirror the sex distribution of the disease 
investigated; therefore, trials must be adequately powered or use stratified randomization by 
sex to enable the investigation of sex differences in treatment efficacy. 
 
[H1] Access to care 
Across the globe, access to stroke care seems to be more difficult for women than men. Key 
treatments such as intravenous thrombolysis are less likely to be offered to elderly women 
than other demographics. Despite the fact that evidence indicates that older women benefit 
from thrombolysis as much as older men129, women are more likely to be excluded from 
thrombolysis treatment (38%) than men (19%) if they are over 80 years of age130. 
 
Secondary prevention of stroke also seems to vary between men and women. Data come 
from different settings in a worldwide perspective. In a community setting in South America, 
men were more likely to receive adequate cardiovascular prevention than were women131. 
This finding was also reported in a primary care setting in northern Sweden, where women 
were less likely to receive statins than were men132. Whether secondary prevention of stroke 
in patients with atrial fibrillation differs between men and women remains unclear, and varies 
geographically. In Germany133, women were less likely to receive adequate antithrombotic 
treatment than were men, whereas in Sweden134, sex was not observed to have an effect on 
secondary treatment, but other socioeconomic factors did  . 
 
Data are lacking regarding access to rehabilitation after stroke, and a huge variability in 
access is observed across different countries and healthcare systems. For example, a 
comparison between specialized rehabilitation in Latvia and Sweden, showed that Latvian 
men were more likely to be admitted to rehabilitation than were Latvian women while in 
Sweden there was an equal access to rehabilitation among men and women 135. This finding 
is in contrast to the UN Convention on the Rights of Persons with Disabilities, which 
highlights the vulnerability of women to disabilities136. Besides access to rehabilitation, 
women tend to be discharged from specialized rehabilitation units despite having a remaining 
need for support137. In developing countries, the situation regarding access to rehabilitation is 
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even more difficult: for example in sub-saharian Africa there is only one stroke unit. 138. In 
summary, barriers for access to care and rehabilitation for women should be identified and 
equal access provided. 
 
[H1] Conclusions 
Stroke is the leading cause of death and disability in women, who have worse outcomes after 
stroke than do men. Risk factors differ between men and women and across age groups, 
and specific stroke subtypes are more common in women than in men.  
Personalized medicine is needed to improve prevention and treatment of stroke in women. 
Little is known about the treatment and prognosis of stroke subtypes that are specific to 
women. Stroke is very prevalent in older women; however, women and especially older 
women are considerably underrepresented in clinical trials, resulting in a paucity of evidence 
in this group. Further research is needed to establish why outcomes are worse in women 
than in men, and to identify effective interventions to reduce the inequitable burden of stroke 
in women. In many countries, the position of women in society might influence their access to 
care, which could contribute to the poor outcome of women undergoing a stroke worldwide. 
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Figure 1 | Hypertensive disorders of pregnancy  
  
 
Figure 2 | Causes of stroke in pregnancy  
 
Figure 3 | Hypertensive disorders of pregnancy are associated with a high risk of 
stroke. A 38 years old woman was admitted for a first-ever generalized seizure with 
eclampsia at 27 weeks of gestation. The eclampsia was associated with a reversible 
posterior encephalopathy. a | An axial MRI fluid attenuation inversion recovery (FLAIR) 
sequence and apparent diffusion coefficient (ADC) cartography showing bilateral 
symmetrical posterior hyperintense lesions with increased ADC suggesting vasogenic 
oedema (arrows). No vessel irregularity was present at that time (image not shown). The 
patient underwent a caesarean section, and was treated with intravenous magnesium, 
enalapril, nicardipine and furosemide. On day 11, the patient presented with a left middle 
cerebral artery stroke. b | An axial MRI diffusion-weighted imaging sequence performed 
2 hours after symptom onset with a large left hemispheric ischaemic stroke. NIH Stroke 
Scale Score was 7 and intravenous thrombolysis was not administered owing to the prior 
caesarean. Mechanical thrombectomy was performed but failed to achieve recanalization. c | 
A middle cerebral artery occlusion is visible on an axial view of the angiogram at the end of 
the endovascular procedure (arrow). The hypothesis of a paradoxal embolism was excluded, 
owing to the absence of patent foramen ovale and the absence of deep vein thrombosis. d | 
Severe vasoconstriction syndrome was present at the time of stroke, as illustrated by this 
coronal plane, CT angiogram, which shows a segmental and focal stenosis on the anterior 
circulation (arrow).  
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